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Exosomes are nanosized vesicles that are secreted by many types of cells. We have found that 
exosomes secreted by HEK293 and HT-1080 can suppress growth and proliferation of p53-deficient 
cells. Upon overexpression of exogenous p53-GFP in HEK293 cells, we observed p53 protein in 
exosomes that were secreted by these cells. We also found endogenous p53 in exosomes that were 
secreted by HT-1080 cells with a higher level of p53 expression. We were able to detect endogenous 
p53 protein in exosomes that originated from human plasma and were transferred to p53-deficient 
cells. Our findings indicate that p53 protein can be transferred between cells and may play an 




Exosomes are nanosized extracellular membrane vesicles that are released from 
multivesicular bodies into the extracellular space by exocytosis (Huang et al., 2013). Depending on 
the cells that produce them, exosomes can differ both in the composition of proteins, lipids, mRNAs, 
different noncoding RNAs, and miRNAs and in their biological properties. Being involved in 
intercellular communication, exosomes can induce both functional and epigenetic changes by 
transferring RNA and specific proteins between cells (Grange et al., 2011; Kobayashi et al., 2014). 
Numer- ous studies demonstrate that increased expression of a variety of genes can lead to the 
occurrence and accu- mulation of their protein products in exosomes (Gra- ner et al., 2009; 
Mukhopadhyay and Mak, 2009; Stau- bach et al., 2009; Meckes et al., 2010; Adamczyk et al., 2011; 
Higginbotham et al., 2011). Today, it being suggested that exosomes can be involved via different 
mechanisms in the development of cancerous tumors, e.g., in preparing a metastatic niche (Webber 
et al., 2015; Yu et al., 2015). The identification of key factors that determine the formation of the 
exosome proteome is important for the identification of novel mechanisms, which can be involved 
in the formation, development, and suppression of tumors (Raimondo et al., 2011; Ung et al., 2014). 
 
The p53 protein is of particular interest due to its prominent role in tumor suppression, because 
of which it is referred to as “the guardian of the genome” in the literature (Liang et al., 2013). Over more 
than 35 years of studies, it has been found that p53 is a transcription factor that controls the cell cycle 
and cell death following oncogene activation, DNA damage, and other types of stress (Vousden and 
Prives, 2009). Some authors believe that p53 can enhance the secretion of exosomes by activating the 
transcription of several genes that are involved in their production (Yu et al., 2006; Lespagnol et al., 
2008; Naghibalhossaini et al., 2011; Lim et al, 2012). However, to date, p53 has not been found in 
exosomes that are secreted by cell lines (Kalra et al., 2012; Keerthikumar et al., 2015), with only one 
study demonstrating its presence in exosomes of human blood plasma (Jorgensen et al., 2015). Thus, 
this problem requires a more detailed study. The presence or absence of this protein in exosomes can 
depend on its expression in producer cells. This study was aimed at detection of p53 in exosomes that 
are secreted by cells with natural and artificially increased expression of this gene and at increasing the 
sensitivity of the method for detection of p53 in exosomes of human body fluids (blood plasma). To 
confirm the presence of p53 in exosomes of blood plasma, we employed an approach that uses 
accumulation of exosomes in recipient cells that do not produce the protein under study. Moreover, to 
test the hypothesis of the possibility of suppression of carcinogenesis by exosomes that contain p53, we 
analyzed how exosomes that are obtained from cell lines with wild-type p53 (HEK293 and HT-1080) 
affect the proliferation of p53-negative cells of cancer lines (GL-V or K562). 
 
MATERIAL AND METHODS 
 
Cell lines, cultivation conditions. This study was performed on passaged cultures of human 
cells: HEK293 (human embryonic kidney cells), GFP-p53ΔY126- HEK293 (an HEK293 clone that 
stably expresses p53 with a single amino-acid deletion), HT-1080 (fibrosarcoma), Gl-V (a primary 
culture of glioma cells that is obtained in our laboratory), and K-562 (chronic myelogenous leukemia) 
(Table 1). The cells were cultivated in DMEM/F12 medium (Biolot, Russia), which was supplemented 
with 10% fetal bovine serum (Biolot, Russia), without antibiotics in a 5% СО2 atmosphere at 37°С. 
The K-562 suspension culture that was obtained from the collection of the Institute of Cytology of the 
Russian Academy of Sciences was cultivated in RPMI 1640 medium (Biolot, Russia), which was 
supplemented with 10% foetal bovine serum (Biolot, Russia). At a combined cultivation of cells of all 
the cell lines with isolated exosomes, the exosome concentration was 1013−1014 exosomes/mL. 
 
Assessment of survival rate of cells. The cells were suspended using a Trypsin–Versene 
solution, and the survival rate was quantitatively assessed by counting the number of cells using a 
Scepter handheld automated cell counter (Millipore, United States). 
 
Isolation of exosomes in in vitro systems. As the cells grew, the culture conditioned medium 
was collected and sequentially centrifuged at 2000 and 20000 g to remove dead cells and their debris 
until 500 mL was accumulated. Then, the accumulated conditioned medium was used to isolate 
exosomes by ultracentrifugation. The ultracentrifugation was carried out on a Beckman coulter 
centrifuge (45Ti rotor) at 100000 g for 2 h. After the centrifugation, the sediment was suspended in the 
maximum volume of phosphate buffer saline (PBS) and centrifuged again under the same conditions. 
The exosome sediment that was obtained was used for further analysis. 
 
Cloning. HEK293 cells were transfected by the p53ΔY126 plasmid according to the 
conventional technique using a Effectene Transfection Reagent kit (Qiagen, Germany). Two days after 
the transfection, the cells were passaged into Carrel flasks and supplemented with G418 at 400 μg/mL. 
In the presence of G418, the cells were cultivated for 10 days. Then, the cells were repassaged into 96-
well plates for cloning, i.e., obtaining cell lines that are descendants of a single cell. One of the clones 
that produce mutant GFP-p53 was used in further experiments. To visualize intracellular GFP, the clone 
cells were passaged into glass-bottom dishes that were 35 mm in diameter (MatTek Corp., United 
States). Live-cell analysis was performed. 
 
Identification of p53 in cells. GL-V cells were grown on coverslips in plates in DMEM/F12 
medium (Biolot, Russia), which was supplemented with 10% fetal bovine serum (Biolot, Russia), in a 
СО2 incubator at 37°С. After the incubation with exosomes the coverslips had the medium washed 
from them 1× PBS and were fixed for 10 min with cold 4% formaldehyde at 4°С. Then, the coverslips 
were washed three times with 1×PBS for 15 min. The preparations were treated with 0.5% Triton X100 
for 10 min and blocked with 5% bovine serum albumin (BSA, Biolot, Russia) in PBS for 15 min at 
room temperature. Monoclonal antibodies against p53 (Sigma, Japan) were diluted 1 : 2000 in 1% BSA 
in 1× PBS. The preparations were stained at 4°С overnight. After the staining with primary antibodies, 
the coverslips were washed with 1× PBS (twice, for 15 min). Secondary antibodies (goat anti-mouse 
Alexa Fluor594, Invitrogen, United States) were diluted 1 : 500 in 1% BSA in 1× PBS. The samples 
were stained with the secondary antibodies for 1 h at room temperature. Then, the coverslips were 
washed in 1× PBS (five times for 20 min) and stored in 1× PBS overnight at 4°С. The samples were 
embedded into Vectashield medium with DAPI (1.5 μg/mL) (Vector Laboratories, Inc., United States), 
and, 1 day after this, they were analyzed on a Leica confocal microscope (Germany). 
 
Assessment of expression of the ТР53 gene. The level of the p53 protein was assessed by 
immunoblotting. For this, cells (1–2 × 106) were washed twice with phosphate buffer saline (PBS) and 
incubated at 4°С for 30 min with a lysing buffer (10 mM Tris-HCl pН 7.4, 0.1% Triton X-100, 5 mM 
phenylmethylsulfonyl fluoride (PMSF), 5 mM MgCl2, 5 U/mL DNase I, 20 mM β-mercaptoethanol). 
The lysates that were obtained were boiled in a standard loading buffer (0.25 М Tris, рН 6.8, 8% SDS, 
40% glycerin, 20% β-mercaptoethanol, 0.2% bromophenol blue) for 5 min. Protein electrophoresis was 
performed in a 10% polyacrylamide gel that contained 0.1% SDS with further protein transfer to a 
PVDF membrane. After the transfer, the membrane was soaked in methanol (10 s) and stained for 1 
min in a 0.1% Coomassie R solution in 30% methanol that contained 10% acetic acid; then, it was 
washed twice in 50% methanol (for 1 min). The visualization of the proteins on a membrane makes it 
possible to evaluate the transfer and the loading of the tracks. The membrane was completely dried for 
further immunodetection without high background. The visualization of p53 on the membrane was 




The absence of data in the literature on the presence of p53 in exosomes may be due to its low 
expression in cells. To study whether p53 can be found in exosomes, we artificially enhanced its 
expression in producer cells. To obtain a cell line that stably expresses p53, we used a plasmid that 
carried p53 with a mutation resulting in the tyrosine deletion at the 126 position of the peptide chain 
(p53ΔY126) and leading to a decrease in the functional activity of the protein under study. To create a 
plasmid that carries the mutant gene, the pEGFP-N1 vector was used; this made it possible to track the 
expression of the protein of interest in vitro. We chose to transfect this plasmid into HEK293 cells with 
low expression of wild-type p53. After selection of the clone, we obtained a stable cell line GFP-
p53ΔY126-HEK293 with high expression of GFP-p53ΔY126 (Fig. 1a). To determine whether 
exosomes that were secreted by GFP-p53ΔY126-HEK293 contained GFP-p53ΔY126 we isolated 
exosomes from the conditioned medium where the cells had grown by ultracentrifugation as described 
earlier (Lasser et al., 2012; Shtam et al., 2013). To confirm the presence of GFP-p53ΔY126 in exosomes 
that were secreted by GFP-p53ΔY126-HEK293 cells, we used immunoblotting. Control was 
represented by whole cell lysates of HEK293 and GFP-p53ΔY126-HEK293 cells that were prepared in 
parallel with the exosome preparation. As can be seen in Fig. 1b, after staining with monoclonal 
antibodies against p53, the exosomes and the GFP-p53ΔY126-HEK293 cells had both the GFP-
p53ΔY126 protein, 80 kDA, and the p53 protein found (Fig. 1b). 
These data made it possible for us to raise a question whether endogenous p53 can be found in 
exosomes and whether it can be transferred via exosomes to recipient cells. The fact that the GFP-
p53ΔY126 protein was found in exosomes that were secreted by the GFP-p53ΔY126-HEK293 cells 
made it possible to propose that the probability of p53 detection in exosomes correlate with its 
expression in the producer cells. To test this hypothesis, we took several cell lines with different 
expression of p53, HT-1080 with high expression and HEK293 with low expression. The K562 and 
GL-V lines where p53 is absent were used as a control. Exosome preparations were obtained from these 
lines by conventional techniques; the presence (absence) of p53 in the exosomes was tested by 
immunoblotting using monoclonal antibodies. The cell lysates of each of the lines were used as a 
control. The p53 protein was only found in exosomes that were secreted by the HT-1080 cell line with 
high expression of this protein (Fig. 2a). To confirm this result and to study p53 transfer between cells 
via exosomes, exosomes that were produced by the HT-1080 line were added to the GL-V cell culture. 
After incubation with the exosomes, the cells were thoroughly washed and fixed with formalin for 
further immunofluorescent detection of p53 using specific monoclonal antibodies. Cells of the same 
line that were not incubated with the HT-1080 exosomes were used as a control. Confocal images that 
were obtained after the application of antibodies against p53 demonstrated fluorescence inside the GL-
V cells that were treated with the HT-1080 exosomes, which was never observed in untreated cells. 
This indicates the occurrence and accumulation of p53 in recipient cells upon their incubation with the 
HT-1080 exosomes (Fig. 2b). 
After the detection of p53 in exosomes that were secreted at least by one cell line, we decided 
to test whether it is possible to detect this protein in exosomes of human body fluids, e.g., to confirm 
its presence in exosomes of blood plasma (Jorgensen et al., 2015). Immunoblotting has not given a 
positive result: no p53 was observed in exosomes of blood plasma. However, under the assumption of 
rather low sensitivity of the applied method, we decided to test the delivery of p53 by the exosomes of 
human blood plasma and its accumulation in the GL-V cells using confocal microscopy. For this, after 
the combined incubation of the GL-V cells that had no endogenous p53 with the exosomes that were 
isolated from the blood plasma, immunofluorescent labeling with antibodies against p53 was 
performed. We were able to identify in the sample cells that contained p53 obtained via exosomes (Fig. 
3). 
The presence of wild-type p53 in exosomes raises the question of its functional role, in 
particular, of the ability of these exosome to affect the growth of cells that do not have p53. To answer 
this question, we isolated exosomes that were obtained from four lines with different statuses of p53 by 
multistage centrifugation as described earlier. For this stage of the study we chose the K562 and GL-V 
lines that do not synthesize p53 and the HT-1080 and HEK293 lines that contain wild-type p53. HT-
1080, HEK293, K562, and GL-V cells were seeded into 24-well plates at the same concentration. Then, 
equal quantities of exosomes that were isolated from one of the cell lines were added to the all cell lines. 
Ten days after the addition of the exosomes the number of living cells was calculated for all the cell 
lines. The results of evaluation of the survival rate of the cells are given in Fig. 4. The addition of 
exosomes that were obtained from all the cell lines that were used in the experiment did not affect the 
survival of the HT-1080 and HEK293 cells. However, the addition of the HT-1080 and HEK293 
exosomes to the K562 and GL-V cells was observed to lead to a decrease in the survival of the K562 
and GL-V cells; the addition of their own exosomes did not affect the survival of the K562 and GL-V 
cells (Fig. 4). The obtained results make it possible to hypothesize that exogeneous p53 that enters cells 




Eukaryotic cells are known to interact with each other not only by means of a direct contact, 
but also by releasing vesicles including exosomes, microvesicles, apoptotic bodies, etc. (Abels and 
Breakefield, 2016). Exosomes contain a wide range of functional proteins, RNA, and miRNA, and they 
are actively released by exocytosis from almost all cell types, including dendritic cells, lymphocytes, 
and tumor cells (Raposo and Stoorvogel, 2013). Moreover, the ability of exosomes to effectively 
transfer exogeneous RNA and proteins to recipient cells has been observed (Alvarez-Erviti et al., 2011; 
Shtam et al., 2013; Haney et al., 2015; Srivastava et al., 2016). The role of exosomes in the formation, 
development, and repression of different types of cancer is of great interest (Webber et al., 2015; Yu et 
al., 2015). 
The р53 protein has not been identified previously among exosome proteins that are secreted 
by cell lines (Kalra et al., 2012; Lasser et al., 2012). The results of numerous studies demonstrate that, 
by enhancing the expression of some genes in cells, it is possible to increase the amount of the protein 
that is encoded by them in the exosomes (Graner et al., 2009; Mukhopadhyay and Mak, 2009; Staubach 
et al., 2009; Meckes et al., 2010; Adamczyk et al., 2011; Gyorgy et al., 2011; Higginbotham et al., 
2011). In this study, we observed p53 in exosomes that were obtained from cells with increased 
expression of the corresponding gene and tried to answer the question of whether the exosomes from 
cells with wild-type p53 could affect proliferation of p53-negative cells. 
Using the p53 protein as an example, we confirmed the possibility of an increase in the protein 
content in exosomes by changing its expression in the cells. However, the data that were obtained for 
mutant p53 (p53ΔY126) may not fully correspond to wild-type p53. We actually observed that GFP-
p53ΔY126 was present not only in the nucleus, but also in the cell cytoplasm (Fig. 1b). The literature 
states that cytoplasmic proteins are included into the secreted vesicles with higher probability (Kalra et 
al., 2012). The fact that p53 has not been found in exosomes before may be accounted for by low 
expression of this short-living transcription factor, which is predominantly localized in the nucleus, in 
its unmutated state. Perhaps there are other explanations. In this study we have observed endogenous 
p53 in exosomes that were obtained from HT-1080 cells with wild-type p53. Our previous results are 
evidence of high expression of p53 in these cells as compared to other cells with wild-type p53 (Kovalev 
et al., 2015; http://p53.free.fr/Database/Cancer_cell_lines/p53_cell_lines.html). The high expression of 
p53 in producer cells and the use of Western blotting for its detection, which is not a conventional 
method for proteomic investigation of exosomes, are likely to have made it possible to detect p53 in 
exosomes. On the whole, the data that we obtained indicate a potential presence of p53 in exosomes of 
body fluids, in particular, in exosomes that are produced by cells with high expression of this protein. 
In view of this, we tried to detect p53 in exosomes of human blood plasma. The result is quite intriguing: 
although p53 accumulation was possible to determine in recipient cells only by confocal microscopy, 
this protein was surely present in exosomes of human blood plasma. 
As has been shown in several previous studies, exosomes are potential protein transporters that 
are involved in oncogenesis (Soldevilla et al., 2014; Gopal et al., 2016; You et al., 2016). In view of 
this, we attempted to answer the question of whether the exosomes from cells with wild-type p53 can 
affect the recipient cells. The survival of the HT-1080 or HEK293 cells with wild-type p53 that were 
co-cultured with any of the exosomes did not differ from the control. At the same time, the survival of 
the GL-V or K562 cells without endogenous p53 reduced in the presence of the HEK293 exosomes 
and, in particular, in the presence of the HT-1080 exosomes. Our results demonstrate for the first time 
that the exosomes from cell lines with wild-type p53 suppress the growth of p53-negative cells of cancer 
lines. This indicates the possibility of tumor regression by exosomes that contain endogenous wild-type 
p53. These results make it possible to suggest that exosomes by transferring one of the most important 
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Fig. 1. Results of the detection of p53-GFP in HEK293-GFP-p53 cells and in exosomes that 
are produced by these cells. (a) Visualization of p53-GFP in HEK293 cells before and after introduction 
of the GFP-p53ΔY126 plasmid; (b) detection of p53 by immunoblotting. 
 
Fig. 2. Visualization of the presence and transfer of endogenous p53 in exosomes. (a) Detection 
of endogenous p53 in cells of different lines and the corresponding exosomes by immunoblotting; (b) 
demonstration of exosome transfer of p53 from HT-1080 cells to GL-V cells that do not have p53 by 
immunofluorescent staining of p53 and confocal microscopy (red signal). DAPI was used to visualize 
nuclei (blue signal). 
 
Fig. 3. Immunofluorescent detection of p53 in GL-V cells before and after their coculturing 
with exosomes of human blood plasma. (a) Gl-V cells before coculturing with exosomes; (b) control 
cells of the GL-V line after coculturing with exosomes that were treated according to the same 
technique, but without application of antibodies against p53; and (c) GL-V cells after coculturing with 
exosomes. To visualize cell nuclei, DAPI (blue signal) was used; red signal is р53. 
 
Fig. 4. Survival rate of Gl-V, K562, HEK293, and HT-1080 cells upon their cultivation in the 
presence of exosomes of one of these cell lines. (1) Control, (2) cultivation in the presence of exosomes 
of GL-V cells, (3) cultivation in the presence of exosomes of K562 cells, (4) cultivation in the presence 
of exosomes of HEK293 cells, and (5) cultivation in the presence of exosomes of НТ-1080 cells. 
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